P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML. (23rd June 2022)

• Record Type: Journal Article
• Authors: Daver, N. G.; Montesinos, P.; Aribi, A.; Martinelli, G.; Altman, J.; Roboz, G.; Wang, E. S.; Burke, P. W.; Jeyakumar, D.; Walter, R. B.; DeAngelo, D. J.; Erba, H. P.; Advani, A.; Gastaud, L.; Thomas, X.; Todisco, E.; Pemmaraju, N.; Mendez, L.; de la Fuente, A.; Gaidano, G.; Curti, A.; Boissel, N.; Recher, C.; Schliemann, C.; Vyas, P.; Sloss, C. M.; Wang, J.; Malcolm, K. A.; Zweidler-McKay, P. A.; Sweet, K. L.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 454
• Page End: 455
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000845108.16448.06
• Languages: English
• ISSNs: 2572-9241